IGX — Intelgenx Technologies Share News
0.000.00%
Last trade - 00:00- CA$41.92m
- CA$62.83m
- $1.04m
Brief: Intelgenx Initiates Restructuring Proceedings Under CCAA To Implement Review Of Its Strategic Alternatives
Brief: Intelgenx Initiates Restructuring Proceedings Under The CCAA
Brief: IntelGenx Says First Parkinson’s Disease Patients Dosed With Montelukast VersaFilm in Mid-Stage Clinical Trial
Brief: IntelGenx Updates Status Of Buprenorphine Buccal Film ANDA
Brief: Intelgenx Enters Into A Third Amended And Restated Loan Agreement With Atai Life Sciences
Brief: IntelGenx Enters into Development and License Agreements for VetaFilm
Brief: IntelGenx Announces Changes To Its Board Of Directors
Brief: Intelgenx Announces Shareholder Approval Of Financing Transactions
Brief: Intelgenx Announces First Agreement For CDMO Packaging Services
Brief: IntelGenx Provides Update On Research Collaboration
Brief: IntelGenx Announces A Change To Its Board Of Directors
Brief: Intelgenx Technologies - Anticipates Entering Into One Or More Commercial Partnership Agreements For Vetafilm Technology Before End Of 2023
Brief: Intelgenx Receives Amended Del License To Conduct Third-Party Testing
Brief: Intelgenx Reports First Quarter 2023 Financial Results
Brief: Intelgenx Receives Complete Response Letter From FDA For Xiromed-Partnered Buprenorphine Buccal Film
Brief: Intelgenx Announces FDA Approval Of Rizafilm® For The Treatment Of Acute Migraine
Brief: Intelgenx Technologies Dwight Gorham Has Been Appointed As Chief Executive Officer, Effective Immediately
Brief: IntelGenx Receives USPTO Allowance Notice For Loxapine Orange Book Eligible Patent
Brief: Intelgenx And Arwan Enter Into A Supply Agreement For RIZAPORT® In MENA Countries